OnKure Therapeutics Stock Forecast

Stock Price Forecast

According to 6 analysts polled by S&P Global, OnKure Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $20.2. The average 1-year stock price forecast is 380.95% higher than the current stock price, while the lowest is $11 (+161.90%) and the highest is $30 (+614.29%).

Price Target: $20.2 (+380.95%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$11	$20.2	$17	$30
Change	+161.90%	+380.95%	+304.76%	+614.29%

* Price targets were last updated on May 10, 2026.

Analyst Ratings

The average analyst rating for OnKure Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Nov '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	6	6	6	6	6	5
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	6	6	6	6	6	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Sam Slutsky LifeSci Capital	LifeSci Capital	Buy Maintains $16	Buy	Maintains	$16	+280.95%	May 10, 2026
Boris Peaker JonesTrading	JonesTrading	Hold Downgrades n/a	Hold	Downgrades	n/a	n/a	May 6, 2026
Matthew Biegler Oppenheimer	Oppenheimer	Buy Reiterates $30	Buy	Reiterates	$30	+614.29%	May 6, 2026
Robert Burns H.C. Wainwright	H.C. Wainwright	Buy Maintains $34 → $27	Buy	Maintains	$34 → $27	+542.86%	Mar 16, 2026
Jonathan Miller Evercore ISI	Evercore ISI	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Jan 27, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

375.00K

Revenue Next Year

666.67K

from 375.00K

77.78%

from 375.00K

EPS This Year

-2.50

from -4.40

EPS Next Year

-2.13

from -2.50

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	375.00K
Operating Income	-29.77M	-36.93M	-53.54M	-62.95M	-63.85M
Net Income	-29.51M	-35.31M	-52.67M	-59.52M	-62.51M
EPS	-	-	-	-4.40	-2.50
Free Cash Flow	-	-22.69M	-23.71M	-31.10M	-52.60M
No. Analysts	-	-	-	-	4

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	1.5M
Avg	375,000
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	433.3%
Avg	77.8%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-2.50
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-